Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…
As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.
By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
Two phase III studies could determine whether the Canadian biotech has an approvable product, but the setting will initially be narrow.
The Hero study gives Myovant an opportunity to change the way hormone-sensitive prostate cancer is treated.
Takeda’s pivotal trial has suggested that TAK-003 could work in both dengue-naïve and previously infected patients, making Sanofi’s Dengvaxia look irrelevant.
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.